RecruitingPHASE1, PHASE2NCT07070323
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Studying Precursor T-cell acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing GoBroad Hospital
- Intervention
- Autologous CD5 CAR T-cells(drug)
- Enrollment
- 54 target
- Eligibility
- 1-70 years · All sexes
- Timeline
- 2025 – 2026
Study locations (4)
- Beijing GoBroad Hospital, Beijing, Beijing Municipality, China
- Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai, Shanghai Municipality, China
- Shanghai Liquan Hospital, Shanghai, Shanghai Municipality, China
- The General Hospital of Western Theater Command PLA, Chengdu, Sichuan, China
Collaborators
The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai · Shanghai Liquan Hospital · Central People's Hospital of Zhanjiang · First Affiliated Hospital of Guangxi Medical University
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07070323 on ClinicalTrials.govOther trials for Precursor T-cell acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
See all trials for Precursor T-cell acute lymphoblastic leukemia →